REUTERS - Shares in Wockhardt fell by their daily limit of 5 percent on Monday after Britain's drug regulator revoked its good manufacturing practice certificate for one of the Indian drugmaker's production facilities.
The Medicines and Healthcare Products Regulatory Agency will instead issue a restricted certificate, meaning Wockhardt will only be able to supply only "critical" products from the facility, the company said in a statement at the weekend.
Wockhardt earns about 12 million pounds in UK and European Union sales from the Chikalthana, Aurangabad facility, located in western India.
A number of top Indian generic drugmakers have faced compliance issues in recent years, with most complaints triggered by investigations by the U.S. Food and Drug Administration. (Reporting by Aradhana Aravindan; Editing by Edwina Gibbs)